EGF and prostate carcinoma: The human prostate expresses functionally active CB1 receptors [6], and anandamide reduces the rate of epidermal growth factor- (EGF) and prolactin-stimulated growth of human prostate cancer cell lines in a manner involving activation of CB1 receptors [7], [8].